In a cohort of 500 invasive breast cancer patients, they found that the recurrence-free survival of the high anti-HER2 autoantibody (HER2-AAb) group was significantly longer than that of the low HER2-AAb group (p value = 0.015). Here, ERBB2 is linked to invasive breast carcinoma.